Business
Mirum Pharmaceuticals Announces Virtual Investor Day 2020
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRUM) today announced that it will host its inaugural Virtual Investor Day on
About this update from Mirum Pharmaceuticals, Inc.
[{"type":"text","content":" FOSTER CITY, Calif.--(BUSINESS WIRE)--\nMirum Pharmaceuticals, Inc. (NASDAQ: MIRUM) today announced that it will host its inaugural Virtual Investor Day on December 9, 2020 from 11:00 a.m. – 1:30 p.m. ET.\n\nThe webcast will include an overview of Mirum’s strategy and commercial plans for its lead investigational medication, maralixibat, as well as development progress for maralixibat and volixibat, both of which are being evaluated for the treatment of pediatric and adult patients with cholestatic liver diseases.\n\nChris Peetz, Mirum’s President and Chief Executive Officer, will be joined by members of the company’s management team, as well as industry experts, Philip Rosenthal, MD, Director of Pediatric Hepatology, University of California, San Francisco, and Catherine Williamson, MD, FRCP, FMedSci, Professor of Women’s Health at King’s College London.\n\nWEBCAST AND DIAL-IN DETAILS\nWebcast link: https://edge.media-server.com/mmc/p/cphus5mg\nToll-free dial-in: (844) 877-4019\nInternational toll: (602) 563-8495\nConference ID: 1191826\n\nA replay of the webcast will be available in the Investor Relations section of Mirum’s website following the live event.\n\nAbout Mirum\n\nMirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company’s lead product candidate, maralixibat, is an investigational oral drug in development for Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), and biliary atresia. The Company has initiated a rolling NDA submission for maralixibat in the treatment of cholestatic pruritus in patients with ALGS and expects to complete the submission in the first quarter of 2021. Additionally, Mirum’s marketing authorization application for the treatment of pediatric patients with PFIC2 has been accepted for review (validated) by the European Medicines Agency.\n\nMirum is also developing volixibat, also an oral ASBT-inhibitor, in primary sclerosing cholangitis and intrahepatic cholestasis of pregnancy. For more information, visit MirumPharma.com.\n\nFollow Mirum on Twitter, Facebook, LinkedIn and Instagram.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20201207005302/en/\n\nInvestors\nIan Clements, Ph.D.\n...